Remove Cannabinoids Remove Epilepsy Remove Pharmaceutical
article thumbnail

Does “low dose” CBD pose a risk to liver health?

Project CBD

Elevated levels of liver enzymes were among the leading causes of withdrawal of young epilepsy patients from previous clinical trials involving high doses of Epidiolex, a pharmaceutical CBD isolate. In all cases, the liver enzyme levels returned to normal within one or two weeks of stopping CBD.

CBD 205
article thumbnail

Top 10 Medical Conditions Treated with Medical Marijuana in 2025

Miss Marijuana

Epilepsy and Seizure Disorders Seizures are one of the most unpredictable and frightening symptoms for people with epilepsy and other seizure disorders. People with epilepsy are finding that adding cannabis to their treatment plan provides more stability and control over their condition. But guess what? The bottom line?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

Patients who suffer from epilepsy , which affects some 3.4 million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). Researchers Analyzed Survey Results from 280 Epilepsy Patients.

article thumbnail

The Science Behind Medical Marijuana: Exploring Cannabinoids and Their Therapeutic Effects

MMJ Recs

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. We’ll explore the diverse range of cannabinoids and their health benefits, providing insights into how these compounds are revolutionizing healthcare.

article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis. Drug Enforcement Agency (DEA). Absolutely.”

article thumbnail

GW suffers major blow as US sinks bid to patent cannabinoids for epilepsy

Cannabis Law Report

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.